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Abstract
Prion infections cause neurodegeneration, which often goes along with oxidative stress. However, the cellular source of
reactive oxygen species (ROS) and their pathogenetic significance are unclear. Here we analyzed the contribution of NOX2, a
prominent NADPH oxidase, to prion diseases. We found that NOX2 is markedly upregulated in microglia within affected
brain regions of patients with Creutzfeldt-Jakob disease (CJD). Similarly, NOX2 expression was upregulated in prion-
inoculated mouse brains and in murine cerebellar organotypic cultured slices (COCS). We then removed microglia from
COCS using a ganciclovir-dependent lineage ablation strategy. NOX2 became undetectable in ganciclovir-treated COCS,
confirming its microglial origin. Upon challenge with prions, NOX2-deficient mice showed delayed onset of motor deficits
and a modest, but significant prolongation of survival. Dihydroethidium assays demonstrated a conspicuous ROS burst at
the terminal stage of disease in wild-type mice, but not in NOX2-ablated mice. Interestingly, the improved motor
performance in NOX2 deficient mice was already measurable at earlier stages of the disease, between 13 and 16 weeks
post-inoculation. We conclude that NOX2 is a major source of ROS in prion diseases and can affect prion pathogenesis.
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Introduction
Prion infections cause the deposition of misfolded, aggregated
prion protein (PrPSc) in the brain, and lead to progressive, lethal
neurodegeneration. These diseases are also known as transmissible
spongiform encephalopathies because their main neuropathological
hallmark is the presence of vacuoles in affected brain regions [1].
Some of the molecular mechanisms underlying these processes are
beginning to be understood, but it is still impossible to arrest the
progression of the disease. Expression of prion protein on neuronal
cell membranes is a prerequisite to neurodegeneration [2,3], and
only the genetic ablation of prion protein has conferred complete
resistance to the disease [4]. In contrast, pharmacological and
genetic approaches targeting mediators of prion-dependent neuro-
toxicity pathways have been found to modify the course of the
disease, but never to reverse it [5–7]. We posit that the identification
of additional molecular components involved in prion neurotoxicity
will be instrumental in designing effective therapeutic approaches.
Signs of oxidative damage have been described in patients affected
by CJD and in experimental models of prion disease [8–11]. Also, an
accelerated course of the disease has been recently reported in mice
devoid of proteins involved in oxidant defense mechanisms (SOD1,
OGG1 and MUTYH), suggesting a deleterious effect of increased
oxidative stress levels [12,13]. However, the source of excessive ROS
production has not been yet described, and the impact of reduced
oxidative stress levels on the course of the disease remains unclear.
The NADPH oxidase enzyme NOX2 is an electron transporter
whose only known physiological function is the production of ROS
[14]. NOX2 produces ROS by the interaction with the transmem-
brane protein, p22phox, the cytosolic subunits, p47phox, p67phox,
p40phox, and one of the small Rho GTP-binding proteins, Rac1 or
Rac2. This enzymatic complex plays an important role in
phagocytes, where production of ROS is necessary for effective
host defense [14]. However, in certain pathological situations, an
excessive activation of NOX2 can lead to oxidative imbalance and
contribute to disease progression [14,15].
We have recently reported that NOX2 is involved in the
neurotoxicity of ligands targeting the prion protein, PrPC [16].
Antibodies to the globular domain of PrPC, but not to other
epitopes, elicited rapid neurotoxicity in vivo and in vitro. After
administration of such neurotoxic antibodies, NOX2-deficient
mice developed smaller lesions than wild-type controls, suggesting
a role of NOX2 in PrPC-dependent neurotoxicity processes.
Such mechanisms could also be involved in the pathobiology of
prion diseases. We therefore investigated the role of NOX2 in
bona fide prion disorders. We found that NOX2 is mainly
PLOS Pathogens | www.plospathogens.org 1 December 2014 | Volume 10 | Issue 12 | e1004531
expressed in microglia, particularly in the cells surrounding
spongiform vacuoles in brains of CJD patients. NOX2-deficiency
in mice resulted in decreased ROS production and reduced
spongiform changes at the terminal phase of the disease. These
effects were associated with an increase in survival and, more
importantly, with improved motor function during the clinical
phase of the disease. Hence NOX2 is a major contributor to the
excessive production of ROS detected in prion disorders, and
therefore influences prion pathogenesis.
Results
Expression of NOX2 in CJD patients
We first investigated the expression and localization of NOX2
in brain samples of patients affected by CJD. Immunohistochem-
istry was performed on sections of cerebellum and frontal cortex
from ten CJD patients with a balanced distribution of PrP types 1
and 2 as reported on Western blots of PK-treated brain
homogenates (S1 Table). Samples of three patients affected by
Alzheimer’s disease (AD) were used as controls (CERAD definite
and Braak & Braak stage V); the first patient also presented with
the cortical type of diffuse Lewy body disease.
The specificity of the anti-human NOX2 antibody was
confirmed by the detection of the appropriate band in Western
blotting of PLB-985 human myeloid cells and concomitant
absence of signal in human NOX2-deficient PLB-985 cells [17],
human NOX1-overexpressing CHO cells and HEK293 cells
overexpressing human NOX3, 4, 5, DUOX1 and DUOX2
(personal communication, Dr. Vincent Jaquet, University of
Geneva). As indicated in representative images (Fig. 1A–H),
conspicuous NOX2 staining was detected in affected brain regions
of CJD patients. Increased expression of NOX2 in CJD, as
compared to AD brain sections, was confirmed by quantitative
analysis (Fig. 1K). The morphology of NOX2-positive cells
suggested that they consisted mainly, if not exclusively, of
microglia. In all CJD brains we noticed a particular strong
expression of NOX2 around a subset of vacuoles (Fig. 1I–J).
In order to clarify the cellular localization of NOX2 in the brain
of CJD patients, we performed multicolor immunofluorescent
analyses using astrocytic (glial fibrillary acidic protein; GFAP),
neuronal (microtubule-associated protein 2 (MAP2) and neurofil-
ament heavy 200 kD subunit (NF)) as well as microglial markers
(ionized calcium-binding adapter molecule 1; IBA1). Confocal
imaging revealed no colocalization between NOX2 and either
GFAP, MAP2 or NF (Fig. 2A–C). NF was also detected around a
subset of vacuoles (Fig. 2C, lower set of panels), but the vacuoles
strongly stained with NF antibodies were not superimposable with
those stained for NOX2. Instead, cellular colocalization was
detected between NOX2 and the microglial marker IBA1
(Fig. 2D). Strikingly, strong NOX2 immunoreactivity was present
in microglial cells surrounding spongiform vacuoles (Fig. 2D,
lower set). These data indicate that microglial NOX2 was
significantly upregulated in brains of CJD patients, suggesting its
involvement in the neuropathological changes developing in
human prion diseases.
Expression of NOX2 in prion disease experimental
models
We next analyzed by Western blotting the expression of NOX2
in mice inoculated with prions and sacrificed at the terminal stage
of disease, and compared it with mice injected with non-infectious
brain homogenate (NBH). NOX2 expression was significantly
increased. The specificity of the signal was confirmed by absence
of the relevant bands from brain homogenates of prion-inoculated,
terminally sick Nox2 deficient mice (Fig. 3A). Also in prion-
infected organotypic cerebellar slices, we found that both NOX2
mRNA and protein levels were significantly increased over those
of NBH-exposed slices (Fig. 3B–C). Hence NOX2 is significantly
induced upon prion infection both in vivo and in cerebellar slices.
As a powerful tool to clarify the cellular localization of NOX2
also in mice, we took advantage of CD11b-HSVTK transgenic
mice, which express the Herpes simplex thymidine kinase
(HSVTK) under the transcriptional control of the Itgam promoter,
active in macrophages and microglia. Administration of ganciclo-
vir to these mice leads to selective microglia depletion [18].
Efficient microglia depletion, induced by ganciclovir treatment
and confirmed by absence of IBA1 signal (Fig. 3C), led to
complete suppression of Nox2 transcript expression (Fig. 3B) and
complete disappearance of all NOX2 protein (as assessed by
Western blotting) from both NBH and prion-treated slices
(Fig. 3C). These data indicate that NOX2 expression is linked to
the presence of microglial cells.
Effect of NOX2 on microglial proliferation, ROS
production and spongiform changes after prion
inoculation
Having assigned the expression of NOX2 to microglial cells, we
investigated whether there would be a difference in microglial
proliferation between wild-type and NOX2-deficient animals after
prion inoculation. Since Nox2 gene targeting was originally
performed in 129-derived embryonic stem cells (CCE.1 line), with
the resulting mice being backcrossed to the C57BL/6J genetic
background [19], we assessed the extent and distribution of 129-
derived genomic material in NOX2-deficient mice. Genome-wide
single nucleotide polymorphism (SNP) analysis indicated that
99.86% of the analyzed SNPs were of C57BL/6 J type, with 129-
derived SNPs clustering exclusively on the X chromosome in a
region spanning ,28.6 million base pairs comprising the Nox2
locus. Extensive mapping studies on different combinations of
mouse and prion strains failed to identify quantitative trait loci on
the X chromosome significantly impacting prion incubation time
[20–24]. Therefore, the 129-derived genomic region on NOX2-
Author Summary
The deposition of misfolded, aggregated prion protein in
the brain causes transmissible spongiform encephalopa-
thies (TSE), a group of disorders including Creutzfeldt–
Jakob disease and mad cow disease. TSE are characterized
by neurodegeneration and progressive, lethal neurological
dysfunction. Signs of oxidative damage are found in TSE,
implying excessive production of reactive oxygen species
(ROS), yet their source is unclear. Here, we analyzed the
role of the NADPH oxidase enzyme, NOX2, in prion
pathogenesis. NOX2 is a membrane-bound electrochem-
ical pump that generates ROS. We found that NOX2 is
upregulated in the brains of patients with Creutzfeldt-
Jakob disease and of prion-infected mice. Interestingly,
NOX2 ablation led to abrogation of ROS production in
mice inoculated with prions, and was associated with a
milder clinical course of the disease and increased life
expectancy. We conclude that NOX2 is a relevant
contributor to the excessive production of ROS. This study
spawns the possibility that inhibiting NOX2 activation
might help attenuate prion disease progression – a
legitimate and important goal even if there is little reason
to expect anti-NOX2 therapies to be curative.
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deficient mice is unlikely to represent a significant genetic
confounder for our study [25].
We first verified that NOX2 deficiency did not affect PrPC
expression levels (S1 A-B Figure) and that partially proteinase-
resistant prion protein accumulation occurred in both wild-type
and Nox2 knock-out animals (S1 C–D Figure).
The extent of microglial reactions was analyzed by immuno-
histochemistry and Western blotting using the IBA1 antibody in
male Nox2+/Y and Nox2-/Y littermates inoculated with 7 log LD50
units of the 22 L strain of prions. In agreement with previous
reports [26], microglia immunostaining increased during disease
incubation and became markedly prominent at the terminal stage
(Fig. 4A). Quantification of IBA1 staining did not show a
significant difference between Nox2+/Y and Nox2-/Y mice at any
time point analyzed (Fig. 4B and S2A Figure). This observation
was confirmed by Western blotting analysis (S3A Figure).
Similarly, we could not see any effect on astrocytic response
(S4A and B Figure).
Although NOX2 deficiency had no discernible influence onto
the extent of microglia proliferation, it might still impact the
production of ROS. We therefore investigated possible differences
in oxidative stress levels by using in vivo injection of the
dihydroethidium (DHE) probe. This molecule reacts with ROS
and is converted into fluorescent adducts which can be measured
in brain sample homogenates [27]. As expected from previous
investigations, signs of oxidative stress production were identified
in prion-infected, terminally scrapie-sick mice, but not in mice
injected with normal brain homogenate. Excessive ROS produc-
tion was only detected at the most advanced stages of disease, and
was completely absent from NOX2-deficient mice (S3B Figure;
Fig. 4C).
In addition, we found fewer spongiform changes in Nox2-
deficient mice (Fig. 4D–E and S2B Figure). These results point to
NOX2 as a major source of ROS in prion disease and a mediator
of prion-induced neuronal toxicity.
Effect of NOX2 expression on clinical manifestations of
disease
In order to assess the neurological deficits induced by prion
disease, we used the rotarod test, which primarily measures motor
coordination and balance abilities [28]. Rotarod performance was
similar in wild-type and NOX2-deficient mice at the early stage of
the disease and up to 12 weeks following prion inoculation
(Fig. 5A). Also, control mice injected with NBH did not display
any difference during the entire test period, up to 20 weeks post-
injection (S5 Figure), confirming previous reports that absence of
NOX2 does not alter motor capacities [29].
In contrast, starting from 13 weeks post prion inoculation, we
noticed a clear difference between the two groups. Wild-type
animals displayed reduced motor capacities, being able to remain
on the rotating rod for significantly shorter periods of time than
NOX2-deficient mice (Fig. 5A). However, this improvement was
transient, and was no longer detectable during the late stages of
the disease (17–18 weeks post-inoculation). Nevertheless, NOX2
deficient mice enjoyed modest yet significantly increased survival
(Fig. 5B–C). The median survival for Nox2+/Y vs. Nox2-/Y mice
was, respectively, 150.5 vs. 157 days post inoculation (dpi) after
injection with 7 log LD50 units of prions and 180 vs. 188 dpi after
inoculation with 3 log LD50 units (P = 0.0052 and 0.2176
respectively, log-rank test).
Similar to a previous report [30], we detected a difference in
incubation time between males and females with both prion titers.
Upon exposure to the 22 L strain of prions, wild-type females
displayed accelerated progression of the disease as compared with
wild-type males (7 log LD50 units = median survival males 150.5
dpi, females 145 dpi; P,0.0001; 3 log LD50 units = males 180 dpi,
females 164 dpi; P= 0.0003, log-rank test). Possibly due to this
accentuated effect on females, we only noticed a difference
between wild-type and NOX2-deficient females after inoculation
with lower doses of prions (Fig. 5D–E): the median survival for
Nox2+/+ vs. Nox2 -/- females was, respectively, 164 vs. 179.5 dpi
after inoculation with 3 log LD50 units of prions, while was 145 dpi
for both groups after inoculation with 7 log LD50 units (P = 0.0030
and P=0.7289 respectively, log-rank test).
Discussion
We have analyzed the role of NOX2 in a mouse model of prion
disease. Our results indicate that NOX2, expressed in microglial
cells, is a relevant source of oxidative stress in this context, and
contributes to prion-induced functional alterations. Prion inocu-
lation of mice faithfully reproduces the neuropathological and
clinical manifestations of the corresponding human pathology, and
indeed, a marked microglial NOX2 staining was present in brain
sections of patients affected by CJD. In light of the recently
recognized differences between human and murine microglia [31],
the consistency of our findings in both species supports the validity
of our results across multiple species including humans.
It has been reported that CJD patients experience higher levels
of microglia proliferation and increased oxidative stress than
patients suffering from Alzheimer’s disease (AD) [10]. Analogous-
ly, we found stronger NOX2 staining in brain sections of CJD
patients than in those of AD patients. Formation and accumula-
tion of misfolded proteins is the main pathogenic event in several
phenotypically diverse neurodegenerative diseases [32]. Such
aggregates trigger a number of toxic and reparative responses,
such as microglia activation, impaired neurotransmission and
neuronal damage [33]. Signs of oxidative stress have been
consistently detected among these processes, yet were mainly
attributed to mitochondrial dysfunctions [34]. Instead, our data
support a role for NOX2 enzyme as possible major source of ROS
in protein misfolding diseases [15]. Therefore, beyond their
relevance to the understanding of prion pathogenesis, our findings
corroborate the idea that NOX2 inactivation is broadly implicated
in neurodegenerative diseases. Moreover, immunohistochemistry
for NOX2 proved to be a robust and reliable tool to visualize
microglia, and might be the best among the available immuno-
histochemical markers for this cell type.
Fig. 1. NOX2 expression is increased in affected brain regions of CJD patients. The expression of NOX2 was analyzed by
immunohistochemistry in paraffin-embedded sections of cortical (A,C,E,G) and cerebellar (B,D,F,H) areas of AD (A–B) and CJD (C–H) patients.
Representative images of CJD brains with predominant cerebellar (C–D) or cortical (E–F) NOX2 expression are shown together with images of CJD
brains with increased NOX2 staining in both areas (G–H). Areas highlighted with dashed boxes in pictures A to H are reproduced at higher
magnification in images A9 to H9. Intense NOX2 staining was present around the rim of spongiform vacuoles (I–J; indicated by black arrows in I). Scale
bar: 50 mm (A–H); 25 mm (A9–H9); 50 mm (I); 10 mm (J). (K) Bar graphs representing mean 6 SEM NOX2 protein expression, quantified as the
percentage of the surface occupied by the NOX2 staining over the total measured area in selected regions of frontal cortex (cx) and cerebellar cortex
(cb) of AD and CJD patients (AD, n= 3; CJD, n = 10; *P = 0.0398; Student’s t test).
doi:10.1371/journal.ppat.1004531.g001
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Intriguingly, we found a very striking pattern of NOX2
expression around neuronal vacuoles. Spongiform vacuolation is
a highly characteristic sign of prion disease pathology, and
vacuoles represent distended intracellular compartments mostly
located within neuronal processes. While the mechanisms under-
lying the development of vacuoles in prion diseases have not been
identified, the intracellular localization of vacuoles in prion
diseases sets them apart from those observed in other neurological
pathologies, such as AD or brain edema [35,36]. Neurofilament
proteins can abnormally accumulate around spongiform vacuoles
[36], but it has also been reported that microglia can surround the
rim of such vacuoles [37,38]. The intimate topographic relation-
ship between vacuoles and microglial processes suggest that the
latter may respond to activating signals emanating directly from
the vacuolated structures.
The cellular localization of NOX2 has been long debated. It has
been suggested that NOX2 is expressed by neurons, yet most such
evidence derives from in vitro studies or from immunostaining
performed in absence of pertinent controls [15,39]. Confocal
imaging of both human brain tissues, as well as microglia depletion
of murine organotypic slice cultures, indicates that within the
brain, NOX2 expression is mainly restricted to microglial cells.
Targeting NOX2 in microglial cells may selectively control
deleterious functions exerted by microglia [40]. Moreover,
NOX2 may be involved in the recently described microglia-
regulated neuronal differentiation and circuitry remodeling during
neurogenesis and synapse formation [41-43]. Differentiation of
neural stem cells and synaptic plasticity can be indeed influenced
by NOX2-dependent ROS production [15], which could there-
fore depend on NOX2 microglial rather than neuronal expression.
Fig. 2. NOX2 expression is localized in microglia cells within CJD brains. Confocal images of immunofluorescence stainings on CJD patient
brain sections: NOX2 is displayed in cyan; GFAP, MAP2, NF and IBA1 in magenta; DAPI in yellow. Panels A, B, C, D, from left to the right: overlay, NOX2
and GFAP, MAP2, NF, or IBA1, respectively; scale bar: 50 mm. Panels C9 and D9: higher magnification of areas in C and D (indicated by box); from left to
the right: overlay, NOX2 and NF or IBA1, respectively; arrows indicate spongiform vacuoles; scale bar: 10 mm.
doi:10.1371/journal.ppat.1004531.g002
Fig. 3. Analysis of NOX2 expression and cellular localization in mice. (A) Western blot of brain homogenates from Nox2+/Y and Nox2-/Y mice
injected i.c. with prions (22 L) or non-infectious brain homogenate (NBH) using antibodies to NOX2 and Actin. Densitometric quantitation of NOX2
signal in Nox2+/Y samples was normalized over Actin signal. Scatter dot plot shows NOX2 relative signal intensity as percentage of NBH samples; each
dot corresponds to a mouse (NBH, n=9; 22 L, n=10; **, P = 0.0044; Student’s t test). (B) Quantitative RT-PCR analysis of Nox2 expression in cerebellar
slice cultures from tga20/TK pups treated with NBH or prions (RML), with or without addition of ganciclovir (GCV). Significantly reduced Nox2
expression levels are detected upon microglia depletion with ganciclovir; each dot corresponds to a pool of 6–9 cerebellar slices cultured in the same
well (n=4 pools; *, P,0.05; ****, P,0.0001; one-way ANOVA followed by Bonferroni’s post-hoc test). (C) Western blot of cerebellar slice homogenates
from tga20/TK pups treated with NBH or prions (RML), with or without addition of GCV using NOX2, IBA1 or Actin antibodies. Densitometric
quantitation of NOX2 signal was normalized over Actin signal. Scatter dot plot represents NOX2 relative signal intensity as percentage of NBH
samples; each dot corresponds to a pool of 6-9 cerebellar slices cultured in the same well (NBH, n= 3 pools; RML, n=6 pools; NBH+GCV, n=6 pools;
RML+GCV, n=6 pools; **, P,0.001; one-way ANOVA followed by Bonferroni’s post-hoc test).
doi:10.1371/journal.ppat.1004531.g003
NOX2 in Prion Diseases
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As previously reported for other pathologies [44,45], NOX2
deficiency does not affect proliferation of microglia cells or
accumulation of misfolded protein aggregates. Microglia-mediated
phagocytosis is a crucial mechanism of defense against PrPSc
deposition and prion-induced damage [46,47]. Indeed, microglia
removal by ganciclovir in CD11b-HSVTK slices led to increased
Fig. 4. Effect of NOX2 expression on microglial proliferation, ROS production and spongiform changes after prion inoculation. (A)
Microglial proliferation was analyzed by immunohistochemistry with the IBA1 antibody on brains of Nox2+/Y (A I-VI) and Nox2-/Y (A VII-XII) mice
injected i.c. with NBH or prions and culled at 4, 8, 12, and 16 weeks post inoculation (wpi) or at the terminal stage of disease. Cerebellar areas are
displayed in the pictures. Scale bar for A I-XII: 250 mm (displayed in panel XII). Dashed boxes in images VI and XII are shown at higher magnification in
panels VI9-VI0 and XII9-XII0; scale bar: 100 mm (displayed in panel XII0). (B) Microglia cell number quantification in cerebellar cortex of Nox2+/Y and
Nox2-/Y mice injected i.c. with NBH or 22 L prions and culled at different time points during disease incubation or at terminal stage. Each dot
corresponds to one mouse (average of 3–5 sections per mouse). Nox2+/Y, n= 4–7; Nox2-/Y, n= 3–6; no significant difference between Nox2+/Y and
Nox2-/Y mice; two-way ANOVA followed by Bonferroni’s post-hoc test. (C) Detection of ROS production in vivo was performed by injecting i.p. the DHE
probe and analyzing the fluorescence of its oxidation products in cerebellar homogenates. Dot plots show relative fluorescent units (RFU) per mg of
proteins; each dot corresponds to one mouse (Nox2+/Y, n= 5–8; Nox2-/Y, n=4–8): ***, P,0.001; two-way ANOVA followed by Bonferroni’s post-hoc
test. (D) Representative images of hematoxylin and eosin-stained sections from Nox2+/Y and Nox2-/Y mice injected i.c. with NBH or 22 L prions. Scale
bar for D I-VI: 250 mm (displayed in panel VI). Dashed boxes in images I to VI are shown at higher magnification in panels I9-VI9; scale bar: 100 mm
(displayed in panel VI9). (E) Number of spongiform vacuoles was quantified in cerebellar cortex of Nox2+/Y and Nox2-/Y mice injected i.c. with NBH or
22 L prions and culled at different time points during disease incubation or at terminal stage. Each dot corresponds to one mouse (average of 7–12
sections per mouse). Nox2+/Y, n=4–7; Nox2-/Y, n= 3–6; ***P,0.0001; two-way ANOVA followed by Bonferroni’s post-hoc test.
doi:10.1371/journal.ppat.1004531.g004
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Fig. 5. NOX2 deficiency attenuates the progression of prion disease. (A) Motor capacities of Nox2+/Y and Nox2-/Y mice were assessed with
the rotarod test at specified time points after i.c. inoculation with 7 log LD50 units of 22 L prions. Scatter dot plot shows the time spent by each
mouse on the rotating rod (latency to fall) expressed in seconds (s). Each dot corresponds to a mouse; a significant overall genotype effect (P = 0.025)
was detected using a general linear mixed model. Student’s t test per each time point also revealed a significant difference at 13 wpi (*, p=0.0483);
15 wpi (*, p=0.0246); and 16 wpi (**, p=0.0048); Nox2+/Y, n= 4–7; Nox2-/Y, n= 5–11. (B–C) Survival curves of Nox2+/Y and Nox2-/Y males, inoculated i.c
with 7 log LD50 (Nox2
+/Y, n= 22, median incubation time 150.5 days post inoculation (dpi), Nox2-/Y, n=22, 157 dpi; P = 0.0052; log-rank test) or 3 log
NOX2 in Prion Diseases
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levels of PK-resistant PrPSc [46]. Similarly, genetic ablation of the
gene encoding for the milk fat globule–epidermal growth factor 8
(Mfge8), impaired the engulfment of apoptotic cells and was
associated with augmented PrPSc accumulation. Since Mfg8 is
secreted by astrocytes, while its receptors are expressed by
microglia, it is possible that microglia-mediated phagocytosis
serves to limit prion deposition. However, microglia overactivation
can transform them in ‘‘saboteurs’’, further contributing to the
progression of the disease [48]. One of the mechanisms associated
with this transformation can be the excessive production of
NOX2-dependent ROS [49].
At the terminal stage of disease, NOX2 ablation completely
prevented ROS production in prion-infected brains, which may
represent a plausible explanation for the observed reduced
spongiform changes and improved survival. In the early preclinical
stages of the disease (4 to 12 weeks post-inoculation), we did not
observe any difference between wild-type and NOX2-deficient
animals in terms of ROS production and motor performance.
However, starting from 13 weeks post inoculation, rotarod analysis
revealed a significantly attenuated decline in locomotor abilities in
NOX2-deficient mice, lasting up to 16 weeks post-inoculation.
Interestingly, when ROS levels were analyzed at this time point,
they were still indistinguishable from wild-type and NOX2-ablated
mice. One possible explanation is that even very small amounts of
ROS, below the detection threshold of the dihydroethidium assay,
may play a role in neurological degradation following prion
infections. Accordingly, increased levels of oxidative stress in the
cerebellum were only found at the terminal stage of mouse scrapie
[11].
Although NOX2 ablation does not ultimately prevent the
development of prion disease, the results presented above show
that NOX2 is a relevant constituent of the neurotoxic cascade in
these diseases. Ablation or overexpression of superoxide dismutase,
SOD1, activity can decrease or increase prion incubation time,
respectively [7,12]. Together with these previous findings, our data
support the crucial impact of superoxide production in prion
diseases. Moreover, they suggest that NOX2, expressed in
microglial cells, is the major source of this superoxide production.
The use of antioxidants as possible therapeutic approach for CNS
diseases has been favored by promising results of rodent studies;
however, disappointing and incongruous outcomes have been
observed in clinical trials [50,51]. Lack of specificity of antioxidant
treatments could be one of the reasons that explain such a failure
in clinical translation. Having identified NOX2 as a possible
specific target may offer an opportunity to reduce the occurrence
of oxidative stress insults in CJD patients. In particular, our data
suggest that inhibition of NOX2 may attenuate, at least
temporarily, the neurological dysfunctions associated with prion
disease, thereby enhancing the quality of life – a legitimate and
important goal even if the overall life expectancy may not be
dramatically improved.
Materials and Methods
Ethics statement
All human tissue samples used in this study dated from before
the year 2005, and were irreversibly anonymized. Approval by an
institutional review board is not mandatory for irreversibly
anonymized samples collected before the approval of the Swiss
Medical-ethical guidelines and recommendations (Senate of the
Swiss Academy of Medical Sciences, Basel, Switzerland, 23 May
2006). Animal care and experimental protocols were in accor-
dance with the ‘‘Swiss Ethical Principles and Guidelines for
Experiments on Animals’’, and approved by the Veterinary office
of the Canton of Zurich (permits 130/2008 and 41/2012). Prion
inoculations were performed under isoflurane anesthesia, and
every effort was made to minimize animal discomfort.
Patients
Samples were obtained from the tissue bank of the Swiss
National Reference Centre of Prion Diseases (Zurich, Switzer-
land). Samples from patients affected by dementia (CJD and AD)
were used to quantify the extent of NOX2 expression. Samples
from patients not affected by dementia were used as controls (S6
Figure). A subset of tissue specimens collected and analyzed
according to biosafety guidelines outlined in our previous study
[52] was used for this analysis.
Mice
Congenic NOX2 knock-out mice [19] on a C57BL/6 J
background were purchased from the Jackson Laboratory
(B6.129S-Cybbtm1Din/J). For prion inoculations, littermates were
obtained by breeding heterozygousNox2+/- females withNox2+/Y or
Nox2-/Y males. For organotypic cerebellar slice cultures and
microglia depletion experiments, tga20/TK pups were obtained
by breeding tga20tg/tg Prnpo/omales on a B6129 mixed background
to heterozygous congenic CD11b-HSVTK females on a C57BL/6
background [18]. For titration experiments, ICR (CD-1) and
C57BL/6 mice were purchased from Harlan laboratories. Mice
were bred in high hygienic grade facilities and housed in groups of
3–5, under a 12 h light/12 h dark cycle (from 7 am to 7 pm) at
2161uC, with sterilized food (Kliba No. 3431, Provimi Kliba,
Kaiseraugst, Switzerland) and water ad libitum.
Whole-genome single nucleotide polymorphisms
analysis
Genomic DNA was purified from tail biopsies using the Gentra
Puregene Mouse Tail Kit (Qiagen) according to manufacturer’s
instructions. Whole-genome SNP analysis was performed using the
Illumina Mouse MD Linkage Panel array (Taconic Laboratories)
and results were compared with data from reference strains
(129S6/SvEvTac, C57BL/6JBomTac, C57BL/6NTac).
Prion inoculations
Inoculum of the 22 L strain of mouse-adapted scrapie prion was
prepared from pooled 10% w/v brain homogenates of 22 L
terminally sick CD-1 mice. Titration experiments were then
performed by inoculating intracerebrally C57BL/6 recipients with
serial dilutions of the 22 L inoculum. Infectivity titer (S2 Table) was
calculated using the statistical method of Karber [53]. Wild-type
and NOX2-deficient mice (8–10 weeks old) were injected intrace-
rebrally with 30 ml of brain homogenate prepared in a solution of
PBS/5% BSA, containing 7 log LD50 units or 3 log LD50 units of
the 22L strain. Control mice received 30 ml of NBH derived from
healthy CD-1 mice. Different sessions of inoculations were
performed using aliquots of the same diluted inoculum depending
on mouse availability. In each session littermates from both
LD50 (Nox2
+/Y, n= 9, median incubation time 180 dpi, Nox2-/Y, n= 5, 188 dpi; P = 0.2176; log-rank test) units of 22 L prions. (D–E) Survival curves of
females Nox2+/+ and Nox2-/- inoculated i.c. with 7 log LD50 (Nox2
+/+, n= 5, 145 dpi, Nox2-/-, n= 7, 145 dpi; P = 0.7289; log-rank test) or 3 log LD50 (Nox2
+/
+, n= 7, 164 dpi, Nox2-/-, n= 6, 179.5 dpi; P = 0.0030; log-rank test) units of 22 L prions.
doi:10.1371/journal.ppat.1004531.g005
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genotypes were used and allocation to experimental groups was
performed before inoculation, in a randomized way. Prion-infected
mice were sacrificed at 4, 8, 12 and 16 weeks post-inoculation (wpi)
or at terminal stage, when they displayed typical clinical signs of the
disease. The operator was blind to the genotypes.
Rotarod
The rotarod test was used to assess motor coordination and
balance at different time points after prion inoculations. The
rotarod apparatus (Ugo Basile) consisted of five cylinders (3 cm
diameter) separated by dividers (25 cm diameter) in five lanes, each
57 mm wide. During the habituation phase, mice were placed on
the rotating drum (4 rpm lowest speed) for 3 sessions lasting 1–
2 minutes each and separated by 10-minute intervals. Test phase
started 30 minutes after the last habituation session, and consisted of
3 trials separated by 15-minute inter-trial intervals. Each test session
lasted for a maximum of 5 minutes while the rod accelerated from 5
to 40 rpm. Latency to fall was determined when the mouse was no
longer able to ride on the accelerating rod because slipping from the
drum or clinging to the rod and rotating with it. Experiments were
always performed at the same time of the day (between 10 am and
12 am), mice were tested in a randomized way and the operator was
blind to the genotypes.
Western blotting
Western blotting analyses were performed on brain tissue
samples or COCS as previously described [46]. For specific
detection of partially protease-resistant prion proteins PrPSc,
proteinase K (PK; Roche) digestion was performed (25 mg ml21
PK for 20 mg protein lysate in a total volume of 20 ml). The
following primary antibodies were used: NOX2 (1:300, BD
Bioscience), IBA1 (1: 5000; Wako); POM1 (200 ng ml21; [54]):
Actin (1:15000, Millipore).
Quantitative real-time PCR
Total RNA was extracted using the RNeasy Universal Plus Mini
kit (QIAGEN) according to manufacturer’s instructions. Genomic
DNA was removed with the gDNA eliminator solution (provided
in the same kit). cDNA was synthesized using 1 mg of RNA with
the PrimeScript RT Reagent Kit with gDNA eraser (Takara Bio
Inc.). Real-time PCR was performed in optical 384-well plates, in
triplicates, using a Prism 7900 HT sequence detection system
(Applied Biosystems) and the SYBR green master mix (Applied
Biosystems). Raw Ct values were used to calculate relative
expression levels of target genes, normalized according to geNorm
analysis [55] to the housekeeping genes Gapdh, Rps9 and Eef1a1.
The following primers were used: Nox2 forward 59-CAG-
GAACCTCACTTTCCATAAGATG-39; Nox2 reverse 59-AAC-
GTTGAAGAGATGTGCAATTGT-39; Prnp forward 59-GCT-
GGCCCTCTTTGTGACTA-39; Prnp reverse 59-CTGGGCT-
TGTTCCACTGATT-39; Gapdh forward 59-TCCATGACAAC-
TTTGGCATTG-39; Gapdh reverse 59-CAGTCTTCTGGGT-
GGCAGTGA-39; Rps9 forward 59-GACCAGGAGCTAAAG-
TTGATTGGA-39; Rps9 reverse 59-TCTTGGCCAGGGTAAA-
CTTGA-39; Eef1a1 forward 59-TCCACTTGGTCGCTTTG-
CT-39; Eef1a1 reverse 59-CTTCTTGTCCACAGCTTTGAT-
GA-39.
Microglia depletion
Cerebellar organotypic slices were prepared from 10–11-days-
old tga20/TK pups, treated with prions or NBH, cultured and
processed for Western blotting or quantitative Real-Time PCR as
previously described [46]. Microglia were depleted from slice
cultures by adding ganciclovir from 0 to 21 days in vitro [18,46].
Slices were harvested at 42 days post-inoculation for Western
blotting or qPCR analyses (described above).
PrPC-ELISA
PrPC was quantified in brain tissue homogenate by sandwich
ELISA using POM1 and POM2 antibodies as described
previously [54].
Histology and immunohistochemistry
Stainings were performed on sections from brain tissues fixed in
formalin, treated with concentrated formic acid to inactivate prions,
and embedded in paraffin. After deparaffinization through graded
alcohols and heat-induced antigen retrieval in citrate buffer (0.01 M;
pH 6), sections were incubated with the following antibodies: anti-
human NOX2 (1:250, Clone 48, Sanquin), GFAP (1:1000,
Millipore), IBA1 (1:2500, WAKO), MAP2 (1:500, Abcam), NF
(1:1000; Abcam). Single stainings were visualized using DAB (Sigma-
Aldrich) and H2O2 (Sigma-Aldrich), after incubation with a
biotinylated secondary antibody (Vector Laboratories) and the
ABC complex solution (Vector laboratories). Hematoxylin counter-
stain was subsequently applied. Double stainings were performed
with fluorescently-labeled secondary antibodies (1:1000, Alexa Fluor
488 or 555; Invitrogen), followed by DAPI (Life technologies) nuclear
staining. Partially protease-resistant prion protein deposits were
visualized by staining brain sections with the SAF84 antibody (1:200,
SPI bio), on a NEXES immunohistochemistry robot (Ventana
instruments) using an IVIEW DAB Detection Kit (Ventana), after
preceding incubation with protease 1 (Ventana). Images of DAB
stained sections were acquired using the NanoZoomer scanner
(Hamamatsu Photonics) and NanoZoomer digital pathology software
(NDPview; Hamamatsu Photonics). Quantifications of NOX2
staining in patient sections or IBA1, GFAP and vacuoles in mouse
sections were performed on acquired images, where regions of
interest were drawn on a Digital Image Hub (Leica Biosystems). The
percentage of brown/white staining and the number of brown/white
objects s over the total area were quantified using in-house–developed
software. For the analyses, the computational algorithms were
implemented using the C++ programming language and the
OpenCV library (source code is available upon request). Operators
were blind to the pathology and to the genotype of the analyzed
sections. Images of fluorescent stainings were acquired with the
confocal CLSM Leica SP5 (Leica Microsystems). Images were
analyzed using the following image-processing softwares: Imaris
(Bitplane), Adobe Photoshop and Adobe Illustrator.
ROS detection
In order to measure the production of ROS in vivo, we used the
DHE probe (Sigma-Aldrich) following a previously published
protocol [27] with minor modifications. Mice were injected i.p.
with 200 ml DHE (3 mM) solution. After 30 minutes of incuba-
tion, brain tissues were harvested, snap frozen in liquid nitrogen
and stored at280uC. Brain samples were homogenized in a buffer
containing 50 mM KH2PO4, 1 mM EGTA and 150 mM sucrose.
For quantification of DHE oxidation products, fluorescence was
detected in 250 ml 2% (w/v) tissue sample homogenates using a
fluorimeter (Ex/Em 485/585, cutoff: 570). Relative fluorescence
units were normalized to protein concentration, determined by
bicinchoninic acid assay (Pierce).
Statistical analysis
Comparison between two groups was assessed with the two-tailed
unpaired Student’s t test, whereas multiple comparisons were
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assessed with the one-way ANOVA or two-way ANOVA followed
by Bonferroni’s post-hoc test. General linear mixed model was used
to analyse rotarod data. Kaplan-Meier method was used to analyze
incubation times and comparison between groups was made with
the log-rank test. GraphPad and IBM SPSS Softwares were used for
analysis and p-values,0.05 were considered statistically significant.
For statistical analysis, logarithm transformation was performed of
numerical data in fig. 1K, and square root transformation of
numerical data in fig. 3B. The details of each analysis (statistical test,
p-values, n) are indicated in the figure legends.
Supporting Information
S1 Figure PrPC and PrPSc in Nox2+/Y and Nox2-/Y mice.
(A) Quantitative RT-PCR analysis of Prnp expression in non-
infected Nox2+/Y and Nox2-/Y cerebellar tissue (n=5). No
significant differences were observed between Nox2+/Y and
Nox2-/Y mice. (B) Levels of PrPC were quantified by ELISA on
non-infected Nox2+/Y and Nox2-/Y cerebellar homogenates (n=5).
No significant differences were observed between Nox2+/Y and
Nox2-/Y mice. (C) Immunolabeled brain sections from Nox2+/Y (I
and III) and Nox2-/Y (II and IV) mice injected with NBH or 22 L
prions at terminal stage using anti-PrP antibody SAF84, after
protease treatment. Scale bar: 250 mm (displayed in IV). (D)
Western blot of PK-digested brain homogenates from Nox2+/Y and
Nox2-/Y mice injected i.c. with NBH or 22 L prions using anti-PrP
antibody POM1 (Ctr, non-PK-digested brain homogenate).
(TIF)
S2 Figure Areas of IBA1 staining and spongiform
vacuoles in Nox2+/Y and Nox2-/Y mice. (A) Scatter dot plot
shows average IBA1 expression, quantified as the percentage of
the surface occupied by the IBA1 staining over the total measured
area in selected regions of cerebellar cortex of Nox2+/Y and Nox2-/Y
mice injected i.c. with NBH or 22 L prions and culled at different
time points during disease incubation or at terminal stage. Each
dot corresponds to one mouse (average of 3–5 sections per mouse).
Nox2+/Y, n=4–7; Nox2-/Y, n=3–6; no significant difference
between Nox2+/Y and Nox2-/Y mice; two-way ANOVA followed
by Bonferroni’s post-hoc test. (B) Area of spongiform vacuoles was
quantified in cerebellar cortex of Nox2+/Y and Nox2-/Y mice
injected i.c. with NBH or 22 L prions and culled at different time
points during disease incubation or at terminal stage. Each dot
corresponds to one mouse (average of 7–12 sections per mouse).
Nox2+/Y, n=4–7; Nox2-/Y, n=3–6; *P,0.05; two-way ANOVA
followed by Bonferroni’s post-hoc test.
(TIF)
S3 Figure Microglial proliferation and ROS production
during prion incubation in Nox2+/Y and Nox2-/Y mice. (A)
Western blots of cerebellar homogenates from Nox2+/Y and Nox2-/
Y mice culled at 4, 8, 12, 16 wpi or at terminal stage using IBA1
and Actin antibodies. Densitometric quantitation of IBA1 signal
was normalized over Actin signal. Corresponding scatter dot plots
show signal intensities as percentage of Nox2+/Y sample mean;
each dot corresponds to one mouse (Nox2+/Y, n=4–5; Nox2-/Y,
n=5; no significant difference; Student’s t test). (B) Detection of
ROS production in vivo was performed by injecting i.p. the DHE
probe and analyzing the fluorescence of its oxidation products in
cerebellar homogenates. Scatter dot plot shows relative fluorescent
units (RFU) per mg of proteins; each dot corresponds to one
mouse (Nox2+/Y, n=4–9; Nox2-/Y, n=3–9); no significant
differences were detected.
(TIF)
S4 Figure Astrocyte reaction in Nox2+/Y and Nox2-/Y
mice. (A) Astrocyte reaction was analyzed by immunohistochem-
istry with the GFAP antibody in Nox2+/Y (A I-VI) and Nox2-/Y
(A VII-XII) mice injected i.c. with NBH or prions and culled
at 4, 8, 12, 16 weeks post inoculation (wpi) or at the terminal
stage of disease. Cerebellar areas are displayed in the pictures.
Scale bar: 250 mm (displayed in panel XII). (B) GFAP staining was
quantified in cerebellar cortex of Nox2+/Y and Nox2-/Y mice
injected i.c. with NBH or 22 L prions. Each dot corresponds to
one mouse (average of 3–5 sections per mouse). Nox2+/Y, n=3–6;
Nox2-/Y, n=3–5; no significant difference between Nox2+/Y and
Nox2-/Y mice; two-way ANOVA followed by Bonferroni’s post-hoc
test.
(TIF)
S5 Figure Rotarod performance of Nox2+/Y and Nox2-/Y
mice injected with NBH. Motor capacities of Nox2+/Y and
Nox2-/Y mice were assessed with the rotarod test at 4, 8, 12, 16 and
20 weeks after injection (wpi) with NBH. Scatter dot plot shows the
time spent by each mouse on the rotating rod (latency to fall)
expressed in seconds (s). Each dot corresponds to a mouse; no
significant differences were detected (Nox2+/Y, n=5; Nox2-/Y,
n=4; Student’s t test).
(TIF)
S6 Figure NOX2 staining in non-demented cases. Repre-
sentative pictures of NOX2 staining in cortical tissue of patients with
(A) and without (B) ischemic lesions. Scale bar: 100 mm.
(TIF)
S1 Table Basic characteristics of CJD and control
patients.
(PDF)
S2 Table 22 L titration in C57BL/6 mice.
(PDF)
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